Reneo Pharmaceuticals, Inc. (RPHM): Price and Financial Metrics


Reneo Pharmaceuticals, Inc. (RPHM): $2.71

0.01 (+0.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RPHM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RPHM Stock Price Chart Interactive Chart >

Price chart for RPHM

RPHM Price/Volume Stats

Current price $2.71 52-week high $6.46
Prev. close $2.70 52-week low $1.79
Day low $2.45 Volume 78,421
Day high $2.79 Avg. volume 44,591
50-day MA $2.33 Dividend yield N/A
200-day MA $2.74 Market Cap 66.48M

Reneo Pharmaceuticals, Inc. (RPHM) Company Bio


Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.


RPHM Latest News Stream


Event/Time News Detail
Loading, please wait...

RPHM Latest Social Stream


Loading social stream, please wait...

View Full RPHM Social Stream

Latest RPHM News From Around the Web

Below are the latest news stories about RENEO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RPHM as an investment opportunity.

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 4, 2022

Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September 30, 2022.

GlobeNewswire | November 8, 2022

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies …

Finanz Nachrichten | November 8, 2022

JMP Securities Initiates a Buy Rating on Reneo Pharmaceuticals (RPHM)

E ratio….

Brian Anderson on TipRanks | September 19, 2022

Reneo Pharmaceuticals (RPHM) Investor Presentation - Slideshow

The following slide deck was published by Reneo Pharmaceuticals, Inc.

Seeking Alpha | September 19, 2022

Read More 'RPHM' Stories Here

RPHM Price Returns

1-mo 16.31%
3-mo -15.84%
6-mo 0.37%
1-year -56.36%
3-year N/A
5-year N/A
YTD 16.31%
2022 -72.75%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7239 seconds.